NUVECTIS PHARMA INC (NVCT)
Health Care · Biotechnology · NASDAQ
Nuvectis Pharma is a clinical-stage biotech developing targeted precision medicines, including SRC/YES1 kinase inhibitors and Factor B inhibitors, to address unmet needs in oncology and chronic inflammatory diseases.
What NUVECTIS PHARMA INC does
Nuvectis Pharma is a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology and complement-related conditions. Its product pipeline includes targeted small-molecule drug candidates aimed at treating solid tumors and various chronic diseases, with several programs currently in clinical development.
Recent developments
In June 2026, the company licensed exclusive worldwide development and commercial rights (excluding China) to NXP100 (a Factor B inhibitor) and NXP200 (a BRAF inhibitor). These additions expand its pipeline beyond the existing NXP900 and NXP800 programs.
From NUVECTIS PHARMA INC's filing of 2026-08-04.
Themes: precision medicine, oncology, kinase inhibitors, complement-related diseases, drug discovery pipeline
Fundamentals
- Price$20.13 as of 2026-10-08 close
- Market cap$656M as of 2026-07-31 (share count; price 2026-10-08)
- 1-year return+223.1% 2025-10-08 close $6.23 → 2026-10-08 close $20.13
- P/En/a negative earnings
- ROE-143.6% FY2025, SEC XBRL
- Debt / equity0.00 as of 2026-09-03
- Beta1.04 as of 2026-09-03
- Last reported earnings2026-08-04 SEC EDGAR Form 8-K (Item 2.02)
How NVCT compares in its sector
- return on equitybottom 25% 510 covered Health Care peers, as of 2026-09-03
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
How NUVECTIS PHARMA INC looks technically
NUVECTIS PHARMA INC (NVCT) is trading 47.1% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed above its 200-day average about 170 trading days ago — a "golden cross", a bullish long-term signal. There is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 18, below the 25 that marks a real trend). Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 43, neither overbought (above 70) nor oversold (below 30). It made a new 20-day low about 3 trading days ago. It is 31.2% below its highest point of the past year.
Trend
8
| Distance from the 200-day | it is trading 47.1% above its 200-day average, the long-term trend line — a longer-term uptrend | +47.1% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $21.80 | $21.80 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $13.69 | $13.69 |
| Swing structure | each recent peak has been lower than the one before it and each dip deeper — the pattern chart-watchers call a downtrend, which describes where price has already been and not where it goes next | lower highs and lower lows |
| Last swing turn | its last significant turn was a swing low 10 calendar days ago — the swings before that are what the structure reading is measured on | 10 sessions |
| Wave structure | its recent swings can be read as a completed three-part downward correction — a pullback in the A-B-C shape Elliott-wave chartists use; the labelling fails if price closes below 19.55. It is the only labelling that fits, though not with textbook proportions, and it describes the swings already printed, not what comes next. | possible three-wave downward correction, complete (atypical proportions) |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 170 trading days ago — a "golden cross", a bullish long-term signal | 170 sessions |
| Trend strength (14-day ADX) | there is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 18, below the 25 that marks a real trend) | 17.5 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 43, neither overbought (above 70) nor oversold (below 30) | 42.9 |
|---|---|---|
| Position in its 14-day range | it is trading near the bottom of its 14-day range ($19.55 to $23.18) — its "stochastic" reading is 16 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been slipping within that range over the last few sessions. | 16.0 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, is in negative territory (momentum leaning bearish) | 23 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $29.27 | $29.27 |
|---|---|---|
| From the 52-week high | it is 31.2% below its 52-week high (its highest price of the past year) | -31.2% |
| Above the 52-week low | it is 262.7% above its 52-week low (its lowest price of the past year) | +262.7% |
| Below the 52-week high | it is 31.2% below its highest point of the past year | 31.2% |
| Since a 20-day breakout | it made a new 20-day low about 3 trading days ago | 3 sessions |
| Since a 55-day breakout | it is trading within its recent 55-day range, with no fresh breakout up or down | 0 sessions |
| All-time high | its highest closing price on record is $29.27 (set on 2026-06-29) | $29.27 |
| Given back of the 52-week move | over the past year its closes ranged ($5.65 to $28.53), and it has given back roughly a third of its rise from last year’s low — 37% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $13.66 to $14.39. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 36.7% |
| From the all-time high | it is 31.2% below its all-time high | -31.2% |
| Nearest price level | it is trading 10.7% above a support level at $17.98 — a price it turned at three times since 2026-07-10, most recently on 2026-08-04. Since 2024-10-08 it has 11 such levels below the current price and 1 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -10.7% |
| All-time low | its lowest closing price on record is $3.08 (set on 2022-02-04) | $3.08 |
| Above the all-time low | it is 553.6% above its all-time low | +553.6% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are narrower than usual versus its own recent 6-month history (tighter than about 90% of it) | 10th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $1.47 between its high and its low — about 7.3% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $1.47 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $19.35 and $23.58 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $19.35 – $21.47 – $23.58 |
| Typical daily range (% of price) | its price moves about 7.3% in a typical session — more volatile than most companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 7.3% |
| Stretch from the 200-day average | it is trading 4.4 daily ranges above its 200-day average price (47.1% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 4.4 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 0.87× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Candlestick patterns
2
| Since a doji | today it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | today |
|---|---|---|
| Since a bearish engulfing | 5 sessions ago it opened above the previous session's close and finished below that session's open — a "bearish engulfing" pair, where one down day more than undid the up day before it | 5 sessions ago |
Price gaps
2
| Gap at the open | it opened on 2026-10-08 1.0% below the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | -1.0% |
|---|---|---|
| Gap filled | a 2.0% gap up opened on 2026-09-17 has been "filled" 15 sessions ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 15 sessions ago |
Price streaks
1
| Closing streak | it closed lower in its latest session, after a session that did not close lower — a single down day rather than a run | 1 session down |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 17.1 percentage points (the stock lost 16.1% while the market gained 1.0%) | -17.1% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock beat the market by 3.5 percentage points (the stock gained 7.4% while the market gained 3.8%) | +3.5% |
| vs market, 6 months | over the past 6 months this stock beat the market by 145.7 percentage points (the stock gained 163.1% while the market gained 17.5%) | +145.7% |
| vs market, 12 months | over the past 12 months this stock beat the market by 208.1 percentage points (the stock gained 223.1% while the market gained 15.0%) | +208.1% |
Signal agreement
2
| Bullish technical signals | 4 of the 9 technical signals we can compute for it are currently in a bullish state: a "golden cross" — its 50-day average is above its 200-day, trading above its 200-day average, outperforming the market over 6 months, near the bottom of its 14-day range (oversold) — these describe past price behaviour, not a forecast | 4 of 9 |
|---|---|---|
| Bearish technical signals | 3 of the 9 technical signals we can compute for it are currently in a bearish state: a fresh 20-day low, MACD momentum is negative, trading below the Ichimoku cloud — these describe past price behaviour, not a forecast | 3 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 4.0% below the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-09-01 and projected forward over today's price, the side traders read as an established downtrend, with the band above acting as the level that would have to be cleared. The band itself is thick, spanning 10.2% of the share price, which is taken to mean a barrier that has held for a while and takes effort to cross. | -4.0% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 10% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $18.35 — a volume-weighted average of daily closes over 188 sessions, not a true tick-by-tick VWAP. | +9.7% |
|---|---|---|
| Vs the average paid since it last reported | the price is 8% below the average price paid since it last reported on 2026-08-04 (its 10-Q), so the typical buyer over that stretch is under water. That average is $21.97 — a volume-weighted average of daily closes over 47 sessions, not a true tick-by-tick VWAP. | -8.4% |
Price levels it has turned at before
NVCT last closed at $20.13 on 2026-10-08. Since 2024-10-08 it has turned at 11 prices below its last close and 1 above; the 3 nearest below and the nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $17.98 | Support | 10.7% below the last close | turned there three times · 2026-07-10 to 2026-08-04 |
| $23.15 | Resistance | 15.0% above the last close | turned there twice · 2026-07-31 to 2026-09-22 |
| $9.22 | Support | 54.2% below the last close | turned there three times · 2026-02-13 to 2026-06-03 |
| $8.40 | Support | 58.3% below the last close | turned there twice · 2025-03-26 to 2025-12-22 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a three-part downward correction — the A-B-C shape chartists use for a pullback — now complete.
This labelling fails — stops being a possible reading at all — if it closes below $19.55.
It is the only labelling that fits these swings, though its proportions are not the textbook ones.
This reading has stood for 8 trading days, since 2026-09-29.
Read from daily closes as of 2026-10-08.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · Pulled back from the 12-month high · Broke down to a new 20-day low · trendless / choppy (low ADX) · beating the market · Printed a doji candle | Learn: moving average · golden cross · adx · rsi · breakout · fifty two week high low
Based on daily closing prices as of 2026-10-08. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingStrong Buy (1.33 mean, 1=Strong Buy…5=Strong Sell) — 5 analysts
- Mean price target$35.40 range $30.00 – $40.00; median $35.00
Analyst estimates, as of 2026-10-04. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Key risks (from latest filing)
["The company has a limited operating history and has incurred losses since inception, with no products approved for commercial sale.","Clinical-stage drug development is highly speculative; the company may fail to demonstrate adequate safety or efficacy, or fail to obtain regulatory approvals.","The company relies heavily on the success of its current and future pipeline candidates and will require significant additional capital to fund operations."]
What changed in the latest 10-Q
AI-assisted comparison of NVCT's 10-Q filed 2026-05-05 against the prior one filed 2025-11-04.
Management's Discussion & Analysis (MD&A)
- Added:
- Newer filing (2026-05-05) adds detail about Phase 1b combination study with osimertinib: 'Phase 1a, Phase 1b (single agent) and Phase 1b (combination study with osimertinib) clinical trials for NXP900, which commenced in September 2023, August 2025 and December 2025, respectively.'
- Newer filing (2026-05-05) adds: 'The ongoing Phase 1b study will evaluate the safety, tolerability and preliminary efficacy of NXP900 both as a single agent targeting specific tumor types and in combination with market-leading epidermal growth factor receptor ("EGFR") and anaplastic lymphoma kinase ("ALK") inhibitors.'
- Newer filing (2026-05-05) includes financial results table for three months ended March 31, 2026 and 2025 with R&D expenses of $4,106 thousand (2026) vs $3,680 thousand (2025), showing $426 thousand change.
- Removed:
- Older filing (2025-11-04) includes detailed Phase 1a results: 'a dose range of 20 to 300 mg/day was evaluated and the dose limiting toxicity dose level was not reached. The most common treatment emergent adverse events were primarily gastrointestinal-related and mild to moderate in intensity; systemic exposure to NXP900 increased with increased doses and a robust pharmacodynamic response of approximately 90% inhibition of SRC kinase phosphorylation was elicited at doses of 150 mg/day and higher, suggesting a potentially wide therapeutic window.' This detailed Phase 1a result section is removed from newer filing.
- Older filing (2025-11-04) describes Phase 1a study as 'evaluated' (past tense); newer filing (2026-05-05) states Phase 1a 'support once-daily oral dosing' with less detail on the evaluation itself.
- Older filing (2025-11-04) includes separate section on NXP800 (GCN2 Kinase Activator) with development history and Phase 1 study details; this section is truncated/removed in newer filing excerpt.
- Reworded:
- Reference date changed from 'December 31, 2024' (older, 2025-11-04) to 'December 31, 2025' (newer, 2026-05-05) in Annual Report form 10-K reference.
- Spelling: 'nonreceptor' (older) changed to 'non-receptor' (newer) in YES1 description.
- Phrase 'yes-associated protein 1' changed to 'YES-associated protein 1' (capitalization of acronym).
- Older filing states 'and an expansion phase (Phase 1b)' while newer filing uses 'to be followed by an expansion phase (Phase 1b)' in describing Phase 1 study structure.
- Older filing: 'The NXP900 Phase 1 study was initiated' vs. newer: 'The Phase 1 study was initiated' (removal of product name in newer version).
- Commas in list formatting: older has 'pancreatic, and ovarian' while newer has 'pancreatic and ovarian' (minor punctuation change).
- Comma placement in 'squamous cell, mesothelioma, and papillary kidney cancers' (older) vs 'squamous cell, mesothelioma and papillary kidney cancers' (newer).
- Notes:
- The newer filing text is truncated and ends mid-table in General and Administrative Expenses section; full financial comparison cannot be completed.
- The older filing text is also truncated at the end of the NXP800 section; complete comparison of that section is not possible.
- Both filings show incomplete tables and financial data due to text truncation.
Risk Factors
- Added:
- Added reference to 'conducting research and development activities' in description of operations (2026-05-05 filing)
- Added statement 'one of which is in active development' regarding product candidates (2026-05-05 filing)
- Removed:
- Removed 'Both of our product candidates are in early clinical development' - changed to reference only one in active development (2025-11-04 filing)
- Removed reference to NXP800 product candidate from pipeline discussion (2025-11-04 filing)
- Removed 'The Phase 1 study for NXP800 started in December 2021 and NXP900 started in September 2023' timeline details (2025-11-04 filing)
- Removed 'Our pipeline product candidates, NXP900 and NXP800, are both in clinical development' (2025-11-04 filing)
- Reworded:
- Changed 'clinical stage' to 'clinical-stage' (hyphenation) (2026-05-05 filing)
- Changed accumulated deficit from '$92.4 million' as of September 30, 2025 to '$105.7 million' as of March 31, 2026 (2026-05-05 filing)
- Changed 'NXP900 and any future product candidates' to 'Our product candidate, NXP900, is in clinical development. NXP900 and any future product candidates' (restructured opening of revenue generation paragraph) (2026-05-05 filing)
- Changed 'Our ability to generate revenue will depend on a number of factors' bullet point capitalization from '●' format with 'Our' to lowercase '●' format throughout (2026-05-05 filing)
- Changed 'risk to benefit' to 'risk-to-benefit' (hyphenation) (2026-05-05 filing)
- Changed 'may not be as accurate' to 'may not be accurate' (removed 'as') (2026-05-05 filing)
- Notes:
- Comparison restricted to provided text excerpts; full sections may have been truncated
- The filing dates indicate approximately 6-month intervals between filings, explaining the accumulated deficit increase
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
No open-market insider purchases or sales recorded in the last 90 days, of which we have read Form 4 filings through 2026-10-04. The 5 days since 2026-10-04 have not been checked yet.
- Last 180 days · read to 2026-10-042 buys ($1M) · 0 sells — 2 buying insiders
Most recent open-market transaction: 2026-06-30. Based on Form 4 filings read through 2026-10-04; anything filed since is not yet included.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about NVCT's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
4 institutional 13F filers reported holding NVCT as of 2026-06-30 (quarter-end position, filed within 45 days).
- Distinct 13F filers 4
- Reported shares held 1,622,008
- Reported value $29,828,727
reported quarterly holdings change (2026-03-31 → 2026-06-30): 0 new, 4 increased, 0 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Ask about NVCT's institutional holders → See what each manager we track holds →
Short interest (FINRA)
NVCT had 2,362,527 shares of reported short interest as of the 2026-09-15 FINRA settlement date (delayed, bi-monthly; not real-time).
NVCT had 7.25% of its shares outstanding sold short as of the 2026-09-15 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 14.77 days to cover at the same settlement.
- Reported short interest (shares) 2,362,527
- Short interest (% of shares outstanding) 7.25%
- Prior settlement (shares) 2,196,224
- Reported change 7.57%
- Days to cover (reported) 14.77
Reported to FINRA as of the 2026-09-15 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Novartis (NVS)
- AstraZeneca (AZN)
- Eli Lilly (LLY)
- Blueprint Medicines (BPMC)
- Krystal Biotech (KRYS)
- Apellis Pharmaceuticals (APLS)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare NVCT vs…
NUVECTIS PHARMA INC is found in…
Frequently asked questions
What does NUVECTIS PHARMA INC (NVCT) do?
Nuvectis Pharma is a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology and complement-related conditions. Its product pipeline includes targeted small-molecule drug candidates aimed at treating solid tumors and various chronic diseases, with several programs currently in clinical development.
What sector is NUVECTIS PHARMA INC (NVCT) in?
NUVECTIS PHARMA INC (NVCT) is classified in the Health Care sector. Its industry is Biotechnology. It trades on NASDAQ.
Who are NUVECTIS PHARMA INC's (NVCT) competitors?
Notable peers of NUVECTIS PHARMA INC (NVCT) include Novartis, AstraZeneca, Eli Lilly, Blueprint Medicines and Krystal Biotech. This peer set is informational only — not financial advice.
Is NUVECTIS PHARMA INC (NVCT) overbought or oversold right now?
NUVECTIS PHARMA INC (NVCT) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 43, in the neutral middle (as of 2026-10-08). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on NVCT come from?
Fundamentals come from SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest; prices are market data, as of 2026-09-03; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.